Interventions for adult Eustachian tube dysfunction: a systematic review

Alexis Llewellyn,1 Gill Norman,1 Melissa Harden,1 Andrew Coatesworth,2 Daniel Kimberling,3 Anne Schilder4 and Catriona McDaid1*

1Centre for Reviews and Dissemination, University of York, York, UK
2Ear, Nose and Throat Department, York Hospital, York, UK
3Gale Farm Surgery, York, UK
4evidENT University College London Ear Institute, Royal National Throat, Nose and Ear Hospital University College London, London, UK

*Corresponding author

Declared competing interests of authors: none

Published July 2014
DOI: 10.3310/hta18460

Scientific summary

Interventions for adult Eustachian tube dysfunction
Health Technology Assessment 2014; Vol. 18: No. 46
DOI: 10.3310/hta18460

NIHR Journals Library www.journalslibrary.nihr.ac.uk
Scientific summary

Background

The Eustachian tube is a narrow tube which links the back of the nose to the middle ear. It is normally closed but opens when we swallow, yawn or chew. It has three main functions: to protect the middle ear from sources of disease, to ventilate the middle ear, and to help drain secretions away from the middle ear. Eustachian tube dysfunction (ETD) is the inability of the Eustachian tube to adequately perform these functions.

Eustachian tube dysfunction may occur when the mucosal lining of the tube is swollen, or does not open or close properly. It can occur after the start of a cold and other nose, sinus, ear and throat infections. If the tube is dysfunctional, symptoms such as muffled hearing, pain, tinnitus, reduced hearing, a feeling of fullness in the ear or problems with balance may occur. Long-term ETD has been associated with damage to the middle ear and the eardrum. Complications include otitis media with effusion (glue ear), middle ear atelectasis (retraction of the eardrum) and chronic otitis media. The precise function and mechanisms of the Eustachian tube, the underlying causes of dysfunction and the broader problems associated with middle ear ventilation are complex and not fully understood. From a diagnostic perspective, ETD is also poorly defined.

There are a number of treatment options aimed at improving Eustachian tube function, but there is limited consensus about management.

Objectives

To determine the clinical effectiveness of interventions for adult ETD and to identify gaps in the evidence in order to inform future research.

Methods

A systematic review was undertaken. Twelve databases, including MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials (CENTRAL), were searched from inception up to October 2012 for published and unpublished studies. In addition, information on studies in progress, unpublished research or research reported in the grey literature was sought by searching a range of resources, including several trial registries and websites of regulatory agencies. The reference lists of all included studies and systematic reviews were also checked to identify studies. Only English-language studies were included.

Studies evaluating interventions to treat ETD in primary, secondary and tertiary care settings were eligible for inclusion: active observation, supportive care, auto-inflation, nasal douching, topical nasal decongestants, antihistamines, intranasal corticosteroids, oral corticosteroids, leukotriene receptor antagonists, antibiotics, simethicone, or surgery. Patients with a diagnosis of ETD were included. Given the current lack of consensus on diagnostic criteria for ETD, a strict definition of ETD was not applied and a pragmatic approach was adopted: primary study definitions of ETD were accepted, provided that they were based on symptomatology, and/or relevant clinical tests such as tympanometry. Patients with patulous Eustachian tube or nasopharyngeal tumours were excluded. Placebo, no intervention or another eligible treatment were relevant comparators. In the first instance, only studies of adults or studies of mixed populations of adults and children where adult data were reported separately were eligible for inclusion. Owing to a paucity of adult studies for non-surgical interventions, the protocol was amended to include comparative studies with mixed populations of adults and children.
The primary outcome was change in severity and/or frequency of symptoms. Other outcomes of interest included quality of life, improvement in middle ear function, improvement in hearing, tympanic membrane mobility, clearance of middle ear effusion, need for additional treatment, early tube extrusion (for pressure equalising tubes), adverse events of interventions, and complications related to ETD.

Randomised controlled trials (RCTs), non-RCTs and observational studies with a control group were included. Studies without a control group (e.g. case series) with at least 10 participants were also included for interventions where no controlled studies were found.

Two researchers independently screened studies for relevance based on the inclusion criteria. Disagreements were resolved by consensus or with a third researcher as needed. One reviewer extracted data; these were checked by a second reviewer. Quality assessment was performed independently by two reviewers. Disagreements were resolved by consensus and, if necessary, a third researcher was consulted.

A narrative and tabular summary of key study characteristics and quality assessment was undertaken. Outcomes were reported as risk ratios (RRs) and mean differences with 95% confidence intervals (CIs). Owing to heterogeneous interventions, outcome measurements and study designs, a quantitative synthesis could not be performed, and results were reported in a narrative synthesis. Studies were grouped by type of intervention (non-surgical and surgical) and then by outcome. Results were interpreted in the context of the quality of the individual studies and clinical heterogeneity.

**Results**

The searches yielded 3022 records. Nineteen studies were included: three RCTs and two non-RCTs evaluating pharmacological interventions and mechanical devices for middle ear pressure equalisation; and 13 case series and one retrospective controlled before-and-after study evaluating surgical interventions. None of the studies was conducted in the UK.

The included studies were small and the sample size ranged from 11 to 108. All of the surgical studies and three of the five non-surgical studies were at high risk of bias. One study had a low risk of bias, and one an unclear risk. All non-surgical studies except one explicitly reported including a minority of children or adolescents. Surgical studies only included adults. The results in several studies were poorly reported, limiting the outcome data that could be extracted.

The included studies rarely specified how they defined ETD or reported standardised procedures for assessment of symptoms. The presence of related conditions at baseline also varied between studies. Many of the surgical studies reported the use of co-interventions, which often included additional surgery for many or all of the patients. Outcome assessment and duration of follow-up were also sources of substantial heterogeneity.

Studies of several relevant surgical and non-surgical interventions were not identified despite extensive searches. In particular, no studies were found of active observation (monitoring to determine whether or not the condition resolves naturally) or supportive care (advice on self-management strategies, such as advice to swallow, yawn or chew).

**Non-surgical interventions**

None of the non-surgical interventions was evaluated by more than one study. There were single studies of nasal steroids, topical decongestant, antihistamine and two different types of mechanical equalisation devices.

There was no evidence from one RCT ($n = 91$) that a 6-week course of nasal steroids was effective at improving the severity and frequency of ETD symptoms among patients with otitis media with effusion.
and/or negative middle ear pressure by the end of the treatment. This was the only study identified as having a low risk of bias, although the trial was underpowered and there were limitations in how the outcome data were reported. There were some data suggesting improvement in middle ear function for patients after receiving direct application of a topical decongestant on the pharyngeal opening of the Eustachian tube in a single RCT \( (n=36) \) \( (RR \ 0.47; 95\% \ CI \ 0.28 \ to \ 0.80) \). However, treatment only improved middle ear function when patients were subject to unphysiologically high pressure changes. The internal and external validity of this study are both unclear, notably due to multiple gaps in reporting of design characteristics and very short-term follow-up. One non-RCT \( (n=32) \) found a significant improvement in middle ear function for patients receiving a single dose of antihistamine and ephedrine compared with placebo \( (RR \ 0.47; 95\% \ CI \ 0.27 \ to \ 0.81) \). However, the reliability of these findings is uncertain, notably due to a high risk of selection bias and very short follow-up duration (3 hours). Two of the pharmacological studies reported measuring adverse events. Minor adverse events were reported in one study, and no events in the second.

Both studies of mechanical pressure equalisation devices were subject to a high risk of bias. One RCT \( (n=20) \) found that self-administration of a manual device applying mild negative pressure to the external ear canal three times a day for 1 week was associated with a significant reduction in severity of fullness in the ear and middle ear function at 1 week compared with no treatment. A non-RCT \( (n=28) \) found a statistically significant improvement in middle ear function \( (RR \ 0.36; 95\% \ CI \ 0.15 \ to \ 0.87) \) and in hearing at 9 to 10 weeks’ follow-up after receiving twice-weekly modified Politzerisation for 6 weeks compared with no treatment. However, the difference in hearing reflected an unexplained deterioration in the control group rather than an improvement in those who received the intervention. Neither study reported data on adverse events of the interventions, making the safety of these interventions uncertain.

**Surgical interventions**

A variety of surgical interventions were evaluated. Eustachian tuboplasty, balloon dilatation and myringotomy were evaluated in multiple studies. The other surgical interventions, laser coagulation and myringotomy for direct application of topical steroids through a MicroWick tube (Silverstein MicroWick™, Anthony Products, Indianapolis, IN, USA), were each evaluated by a single study. All studies had a high risk of bias. Any interpretation of data from case series is limited by the uncontrolled study design; it is impossible to determine how much improvement in symptoms and other measures would have occurred in the absence of the intervention, especially in the case of a condition which may resolve naturally. Extensive use of co-interventions contributed to uncertainty.

Eustachian tuboplasty was the most commonly evaluated surgery (seven studies, \( n=182 \)). Where reported, a significant number of patients had an improvement in symptoms (from 36% to 92%) at follow-up ranging from 2 to 37 months, though improvement was defined in a variety of ways. Four studies reported an improvement in hearing, although improvements were generally small with limited clinical significance (pure tone averages improvements between –6 decibels (dB) and –10 dB, three studies; decrease in the air–bone gap of –12.3 dB, one study). Measures of middle ear function indicated low rates of conversion to type A tympanogram in the three studies that reported this outcome (from 13% to 36% of patients). As well as differences in the techniques used, there were wide variations among the patients in these studies, as well as differences in the outcomes reported and the measures used to assess outcomes. There was insufficient evidence to demonstrate the effectiveness of tuboplasty, or to determine either the details of the surgical technique which should be employed or the patients for whom it should be considered.

Three studies of balloon dilatation were identified \( (n=107) \). Two reported on symptoms at follow-up (12 weeks and mean 30 weeks); both showed high levels of improvement in symptoms (92% and 71% of patients). Tympanometric measurement of middle ear function was reported in all three studies, and all reported conversion to type A tracings (from 36% to 96% of patients), although follow-up duration varied significantly between the studies (from 6 weeks to 1 year). None of the studies reported data on hearing. Two of the studies reported that all or a majority of patients had additional surgery and a minority of patients in the third also had additional treatment.
Two studies assessing procedures for myringotomy were identified. One small study \((n = 13)\) reported efficacy in permitting patients to undergo hyperbaric oxygen therapy, while the other \((n = 108)\) reported symptom alleviation in the subgroup of patients with an ETD diagnosis. The evidence base for topical application of steroids to the Eustachian tube and laser point coagulation each rested on a single study.

None of the interventions appeared to be associated with serious adverse effects, although minor complications of surgery were reported in a minority of patients in several studies. However, it was not clear that adverse events were systematically documented, and three surgical studies did not report any safety data. None of the studies reported follow-up beyond a maximum of 30 months; therefore, the long-term safety profile of the interventions is unknown.

Conclusions

Implications for health care

The evidence for treatments for adult ETD was limited in quantity and overall was of poor quality. Multiple sources of potential bias were identified in nearly all of the included studies. Additional confounding factors were present in many of the evaluations of surgical interventions, while clinical relevance was limited in two of the three pharmacological studies. Given the limitations of the evidence, it is not possible to make conclusions regarding the effectiveness of any of the interventions for the treatment of patients with a diagnosis of ETD.

Recommendations for research

Owing to the extent of the gaps in the evidence and poor quality of available evidence, the studies identified by this review do not provide a clear evidence base to recommend a trial of any particular intervention. One of the principal findings of the review was the variability in inclusion criteria and unclear and variable definitions of ETD used across the included studies. This indicated a lack of consensus as to what the population of interest is and how people should be evaluated for inclusion in any further studies.

A research priority setting exercise is required to identify the most appropriate avenues for further research. In the first instance, this should focus on developing an explicit definition of the population of interest and the diagnostic inclusion criteria that should be used to identify them. The specification of the population of interest should take into consideration the increasing recognition that the signs and symptoms previously attributed to ETD may also be related to other middle ear problems; for instance, gaseous exchanges within the middle ear mucosa may play a role in the development of middle ear ventilation problems. It should also address the question of criteria for consideration of surgical treatment in a patient diagnosed with ETD. The exercise will also need to address the lack of consensus as to what the important clinical outcomes are following treatment, and how these should be measured. This should include agreement on the duration of follow-up required for an intervention to be adequately assessed for both efficacy and safety. Only when a consensus on these key elements has been arrived at should the question of commissioning further primary research intervention studies be considered.

Study registration

This study is registered as PROSPERO CRD42012003035.

Funding

Funding for this study was provided by the Health Technology Assessment programme of the National Institute for Health Research.
Criteria for inclusion in the Health Technology Assessment journal

Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme

The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. ‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

For more information about the HTA programme please visit the website: www.hta.ac.uk/

This report

The research reported in this issue of the journal was commissioned and funded by the HTA programme on behalf of NICE as project number 12/43/01. The protocol was agreed in October 2012. The assessment report began editorial review in February 2013 and was accepted for publication in May 2013. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health.

© Queen’s Printer and Controller of HMSO 2014. This work was produced by Llewellyn et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
**Editor-in-Chief of Health Technology Assessment and NIHR Journals Library**

**Professor Tom Walley**  Director, NIHR Evaluation, Trials and Studies and Director of the HTA Programme, UK

**NIHR Journals Library Editors**

**Professor Ken Stein**  Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

**Professor Andree Le May**  Chair of NIHR Journals Library Editorial Group (EME, HS&DR, PGfAR, PHR journals)

**Dr Martin Ashton-Key**  Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

**Professor Matthias Beck**  Chair in Public Sector Management and Subject Leader (Management Group), Queen’s University Management School, Queen’s University Belfast, UK

**Professor Aileen Clarke**  Professor of Public Health and Health Services Research, Warwick Medical School, University of Warwick, UK

**Dr Tessa Crilly**  Director, Crystal Blue Consulting Ltd, UK

**Dr Peter Davidson**  Director of NETSCC, HTA, UK

**Ms Tara Lamont**  Scientific Advisor, NETSCC, UK

**Professor Elaine McColl**  Director, Newcastle Clinical Trials Unit, Institute of Health and Society, Newcastle University, UK

**Professor William McGuire**  Professor of Child Health, Hull York Medical School, University of York, UK

**Professor Geoffrey Meads**  Professor of Health Sciences Research, Faculty of Education, University of Winchester, UK

**Professor Jane Norman**  Professor of Maternal and Fetal Health, University of Edinburgh, UK

**Professor John Powell**  Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

**Professor James Raftery**  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

**Dr Rob Riemsma**  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

**Professor Helen Roberts**  Professor of Child Health Research, University College London, UK

**Professor Helen Snooks**  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Please visit the website for a list of members of the NIHR Journals Library Board: www.journalslibrary.nihr.ac.uk/about/editors

**Editorial contact:** nihredit@southampton.ac.uk